Latest news with #Gleason
Politico
20 hours ago
- Health
- Politico
The Trump administration wants to ‘kill the clipboard'
WASHINGTON WATCH Roughly 60 entities in the health care sector will pledge to making patient data more accessible and speeding its delivery among patients, clinicians and payers, according to an HHS employee granted anonymity to discuss the sensitive plans. The White House and the Centers for Medicare and Medicaid Services are expected to announce the commitments on Wednesday, Ruth reported last week. The agency hopes the commitments will stoke companies to make it easier for patients to import their data into an app of their choice, where they can manage their day-to-day health and easily share their history with doctors. Pledges, not rules: The Trump administration has sought such commitments to compel the industry to make changes without having to engage in a lengthy rulemaking or guidance process. But the federal government has tried similar tactics in the past. In 2016, the then-secretary of the Department of Health and Human Services, Sylvia Burwell, under President Barack Obama, announced at a health IT conference that dozens of health industry organizations would commit to easing the flow of health information to patients. Nearly 10 years later, those voluntary commitments haven't materialized into better data access. Still, the Trump administration thinks it can appeal to the private sector more effectively. A joint effort: In a video posted Friday, Amy Gleason, strategic adviser to HHS and CMS and the acting administrator of the Department of Government Efficiency, asked viewers to envision the ability to instantly share their medical history via a QR code or manage their medications with an app. 'The future of health care technology can't come only from the government,' said Gleason. 'The apps, services and tools that make this data useful in people's lives comes from you, the private sector.' Even though evidence that public pledges are more effective than regulation is scarce, industry might welcome the approach. 'The risk of … incremental regulatory compliance stuff is that you wind up spending all of your time trying to check boxes,' said Joe Ganley, vice president of regulatory affairs at electronic health record company Athenahealth. What to watch for on Wednesday: The White House announcement is largely being driven by CMS, but the event could have implications for the ONC. Health providers, data networks and payers are committing to expanding their use of Fast Healthcare Interoperability Resources, an open standard for transmitting data, according to a partial draft of a document obtained by POLITICO. The increased use of FHIR may portend a shift in ONC's regulatory scope. In her announcement, Gleason called on the health industry to help the government 'kill the clipboard.' 'Kill the Clipboard' is the name of a 2025 white paper by Ryan Howells, a one-time contender to lead the ONC and a principal at health management association Leavitt Partners based in Washington. It proposed ONC oversee how health care entities use FHIR. Could ONC shift how it regulates and will this come up at the event? We'll be watching. More to watch for: The draft also mandates data networks — entities that facilitate data exchange — create record-locating services. Requiring such services could be a boon for the ONC-supported data network, the Trusted Exchange Framework and Common Agreement, also known as TEFCA. Requiring those services could enable doctors to quickly access their patients' complete medical histories across providers, eliminating time-consuming record requests to multiple clinics. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Exercise, diet and socializing are key to slowing cognitive decline as people age, according to a new study, CNN reports. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. WORLD VIEW Dr. Jean-Claude Mulunda is concerned that the halt of U.S. funding for contraceptives will lead to an increase in the number of unintended pregnancies and unsafe abortions in the Democratic Republic of the Congo, his home country. Mulunda leads the country's chapter of IPAS, an international nonprofit that aims to expand access to legal abortion and contraception. Women there 'see themselves becoming pregnant just because there's no [contraceptive] method available,' Mulunda told Future Pulse. Why it matters: The DRC has depended almost entirely on foreign-funded family-planning commodities, such as birth control pills, intrauterine devices, long-acting injectable drugs and condoms. But since the Trump administration cut foreign aid and dismantled the U.S. Agency for International Development, which funded contraceptives, many clinics across the vast African country have been left without any stock, Mulunda said. He's also worried that more women will seek unlicensed contraceptives from unauthorized suppliers, which could lead to potentially dangerous consequences if the products are unsafe. That could also lead women to lose trust in contraception, Mulunda worries. Meanwhile: The U.S. government is set to destroy 'certain [abortion-inducing] birth control commodities from terminated Biden-era USAID contracts,' a State Department spokesperson told Future Pulse. The spokesperson didn't specify the types of contraceptives covered but added that no HIV drugs or condoms would be destroyed. The Mexico City Policy: The federal government can't provide the contraceptives, including those it considers to be non-abortion-inducing, to entities that don't abide by the U.S.'s Mexico City Policy, the spokesperson said. The policy prohibits U.S. funding from going to so-called foreign non-governmental organizations, or NGOs, that provide or promote abortion with funding from non-U.S. sources. President Donald Trump reinstated the policy — which all Republican presidents since Ronald Reagan have done — upon his return to office in January. Going to waste? The contraceptives, stored in Belgium and set to be destroyed in France, have prompted calls for interventions from those countries' governments. A Belgian foreign ministry spokesperson told NPR on Monday that the country is exploring possible avenues to prevent the contraceptives from being destroyed. And in France, four members of the left-wing green political coalition, the Ecologists, asked President Emmanuel Macron in a public letter to find a way to impede the contraceptives' destruction and supply the products to NGOs interested in bringing them to their intended beneficiaries in low-income countries. 'Mister President, our country cannot become an accomplice, even indirectly, to backward policies, and cannot tolerate that vital medical resources be destroyed when they could save lives, prevent unwanted pregnancies and contribute to women's autonomy,' the lawmakers wrote.
Hamilton Spectator
a day ago
- Business
- Hamilton Spectator
CECO Environmental Reports Second Quarter 2025 Results
ADDISON, Texas, July 29, 2025 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) ('CECO' or the 'Company'), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the second quarter of 2025. Second Quarter Summary(1) (1) All comparisons are versus the comparable prior year period, unless otherwise stated. Reconciliations of GAAP (reported) to non-GAAP measures are in the attached financial tables. Todd Gleason, CECO's Chief Executive Officer commented, 'We delivered another record quarter, led by tremendous orders, which were up 95 percent year-over-year. Our multi-quarter string of record bookings enabled our highest ever quarterly revenue and increased our backlog to an all-time high of $688 million, which is up 76 percent versus last year. Our diverse and well-positioned portfolio of leading environmental solutions for industrial air, industrial water and energy transition markets continue to gain traction in key markets and new geographies. In the quarter, we booked CECO's largest-ever order which will provide emissions management solutions for a large power generation project. That order, combined with continued strong natural gas and water infrastructure and other energy transition projects, helped push second quarter orders to the all-time record. We are excited about our ability to capitalize on these mega-theme opportunities as well as our steady return on investment associated with our ongoing portfolio transformation.' Second quarter operating income was $18.1 million, up $8.8 million when compared to $9.3 million in the second quarter of 2024. On an adjusted basis, non-GAAP operating income was $18.3 million, up $5.7 million or 45 percent when compared to $12.6 million in the second quarter of 2024. Net income was $9.5 million in the quarter, up $5.0 million compared to $4.5 million in the second quarter of 2024. Non-GAAP net income was $8.7 million, up $1.3 million when compared to $7.4 million in the second quarter of 2024. Adjusted EBITDA of $23.3 million, reflecting an adjusted EBITDA margin of 12.6 percent, was up 45 percent compared to $16.1 million in the second quarter of 2024. Free cash flow in the quarter was $(3.0) million, down $5.6 million compared to $2.6 million in the second quarter of 2024. 'I am pleased, and not at all surprised, that our teams of dedicated employees continue to execute at high levels while overcoming macro uncertainties and market challenges. While certain headlines could distract, our teams remain laser focused on delivering for our customers while navigating supply chain disruptions and evolving trade policies. This is strongly reflected with our highest-ever gross margins and expanded income margins, all while maintaining investments in commercial growth, new geographies, operating resources to drive efficiencies, as well as new market leading solutions,' Gleason added. 2025 Full Year Guidance For the full year 2025 outlook, the Company has raised its revenue outlook to $725 to $775 million, up approximately 35 percent at the midpoint. The previous outlook for full year revenue was $700 to $750 million. The Company maintains its expected range for adjusted EBITDA of between $90 to $100 million and a free cash flow outlook of greater than 60 percent conversion of adjusted EBITDA. 'As we enter the second half of 2025, we are energized to maintain our top-quartile growth and operating performance. Our confidence is bolstered by our record backlog and our robust, $5.5 billion sales pipeline which continues to grow in support of strong demand for power generation, natural gas and water infrastructure, semiconductor expansion and general industrial markets. This backlog and pipeline visibility allows us to increase our full-year revenue outlook to between $725 and $775 million, which represents a growth rate of approximately 35 percent compared to last year. We remain very bullish on our full year adjusted EBITDA outlook – which reflects a roughly 50 percent growth rate – despite some anticipated inflationary pressure in the second half of the year. Overall, we are very pleased with how our year is shaping up and look forward to maintaining our investments to support sustainable growth,' concluded Gleason. EARNINGS CONFERENCE CALL A conference call is scheduled for today at 8:30 a.m. ET to discuss the second quarter 2025 financial results. Please visit the Investor Relations portion of the website ( ) to listen to the call via webcast. The conference call may also be accessed by visiting . A replay of the conference call will be available on the Company's website for a period of one year. The replay may also be accessed by visiting . ABOUT CECO ENVIRONMENTAL CECO Environmental is a leading environmentally focused, diversified industrial company, serving the broad landscape of industrial air, industrial water and energy transition markets globally providing innovative solutions and application expertise. CECO helps companies grow their business with safe, clean, and more efficient solutions that help protect people, the environment and industrial equipment. CECO solutions improve air and water quality, optimize emissions management, and increase energy efficiency for highly-engineered applications in power generation, midstream and downstream hydrocarbon processing and transport, electric vehicle production, polysilicon fabrication, semiconductor and electronics, battery production and recycling, specialty metals and steel production, beverage can, and water/wastewater treatment and a wide range of other industrial end markets. CECO is listed on Nasdaq under the ticker symbol 'CECO.' Incorporated in 1966, CECO's global headquarters is in Addison, Texas. For more information, please visit . CECO Environmental Investor Contact: Marcio Pinto Vice President - Financial Planning and Investor Relations 888-990-6670 Steven Hooser and Jean Marie Young Three Part Advisors, LLC 214-872-2710 (1) Other non-recurring expenses, including fair value adjustment of earn-out liabilities from the acquisitions of WK Group, restructuring expenses primarily relating to severance, facility exits, and associated legal expenses, asbestos litigation expenses relating to future settlement payments, and third party professional consulting fees associated with Enterprise Resource Planning system implementations. NOTE REGARDING NON-GAAP FINANCIAL MEASURES CECO is providing certain non-GAAP historical financial measures as presented above as we believe that these figures are helpful in allowing individuals to better assess the ongoing nature of CECO's core operations. A 'non-GAAP financial measure' is a numerical measure of a company's historical financial performance that excludes amounts that are included in the most directly comparable measure calculated and presented in accordance with GAAP. Non-GAAP operating income, non-GAAP net income, non-GAAP operating margin, non-GAAP earnings per basic and diluted share, adjusted EBITDA and free cash flow, as we present them in the financial data included in this press release, have been adjusted to exclude the effects of amortization expenses for acquisition-related intangible assets, contingent retention and earnout expenses, restructuring expenses primarily relating to severance and legal expenses, acquisition and integration expenses which include retention, legal, accounting, banking, and other expenses, foreign currency remeasurement and other nonrecurring or infrequent items and the associated tax benefit of these items. Management believes that these items are not necessarily indicative of the Company's ongoing operations and their exclusion provides individuals with additional information to better compare the Company's results over multiple periods. Management utilizes this information to evaluate its ongoing financial performance. Our financial statements may continue to be affected by items similar to those excluded in the non-GAAP adjustments described above, and exclusion of these items from our non-GAAP financial measures should not be construed as an inference that all such costs are unusual or infrequent. Non-GAAP operating income, non-GAAP net income, non-GAAP operating margin, non-GAAP earnings per basic and diluted share, adjusted EBITDA and free cash flow are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of CECO's results as reported under GAAP. Additionally, CECO cautions investors that non-GAAP financial measures used by the Company may not be comparable to similarly titled measures of other companies. In accordance with the requirements of Regulation G issued by the Securities and Exchange Commission, non-GAAP operating income, non-GAAP net income, non-GAAP operating margin, non-GAAP earnings per basic and diluted share, adjusted EBITDA and free cash flow stated in the tables above are reconciled to the most directly comparable GAAP financial measures. Non-GAAP measures presented on a forward-looking basis were not reconciled to the comparable GAAP financial measures because the reconciliation could not be performed without unreasonable efforts. The GAAP measures are not accessible on a forward-looking basis because we are currently unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures for these periods but would not impact the non-GAAP measures. Such items may include amortization expenses for acquisition-related intangible assets, contingent retention and earnout expenses, restructuring expenses primarily relating to severance and legal expenses, acquisition and integration expenses which include retention, legal, accounting, banking, and other expenses, foreign currency remeasurement and other nonrecurring or infrequent items and the associated tax benefit of these items. The unavailable information could have a significant impact on our GAAP financial results. SAFE HARBOR Any statements contained in this Press Release, other than statements of historical fact, including statements about management's beliefs and expectations, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, both as amended, and should be evaluated as such. These statements are made on the basis of management's views and assumptions regarding future events and business performance. We use words such as 'believe,' 'expect,' 'anticipate,' 'intends,' 'estimate,' 'forecast,' 'project,' 'will,' 'plan,' 'should' and similar expressions to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Potential risks and uncertainties, among others, that could cause actual results to differ materially are discussed under 'Part I – Item 1A. Risk Factors' of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and may be included in subsequently filed Quarterly Reports on Form 10-Q, and include, but are not limited to: the effect of the divestiture of our Fluid Handling business on business relationships, operating results, and business generally, disruption of current plans and operations and potential difficulties in employee retention as a result of the transaction, diversion of management's attention from ongoing business operations in connection with the integration of recent acquisitions, the amount of the costs, fees, expenses and other charges related to the transaction, the achievement of the anticipated benefits of transactions, our ability to successfully integrate acquired businesses and realize the synergies from acquisitions, as well as a number of factors related to our business, including the sensitivity of our business to economic and financial market conditions generally and economic conditions in CECO's service areas; the potential for fluctuations in prices for manufactured components and raw materials, including as a result of tariffs and surcharges, and rising energy costs; inflationary pressures relating to rising raw material costs and the cost of labor; dependence on fixed price contracts and the risks associated therewith, including actual costs exceeding estimates and method of accounting for revenue; the effect of growth on our infrastructure, resources, and existing sales; the ability to expand operations in both new and existing markets; the potential for contract delay or cancellation as a result of on-going or worsening supply chain challenges or other customer considerations; liabilities arising from faulty services or products that could result in significant professional or product liability, warranty, or other claims; changes in or developments with respect to any litigation or investigation; failure to meet timely completion or performance standards that could result in higher cost and reduced profits or, in some cases, losses on projects; the substantial amount of debt incurred in connection with our strategic transactions and our ability to repay or refinance it or incur additional debt in the future; the impact of federal, state or local government regulations; our ability to repurchase shares of our common stock and the amounts and timing of repurchases; our ability to successfully realize the expected benefits of our restructuring program; economic and political conditions generally; our ability to optimize our business portfolio by identifying acquisition targets, executing upon any strategic acquisitions or divestitures, integrating acquired businesses and realizing the synergies from strategic transactions; and the unpredictability and severity of catastrophic events, including cyber security threats, acts of terrorism or outbreak of war or hostilities or public health crises, as well as management's response to any of the aforementioned factors. Many of these risks are beyond management's ability to control or predict. Should one or more of these risks or uncertainties materialize, or should the assumptions prove incorrect, actual results may vary in material aspects from those currently anticipated. Investors are cautioned not to place undue reliance on such forward-looking statements as they speak only to our views as of the date the statement is made. Except as required under the federal securities laws or the rules and regulations of the Securities and Exchange Commission, we undertake no obligation to update or review any forward-looking statements, whether as a result of new information, future events or otherwise.
Bloomberg
5 days ago
- Business
- Bloomberg
Interior Designer's Home in San Miguel de Allende Lists for $3.2 Million
A decade ago, interior designer Rela Gleason took a trip from California to San Miguel de Allende, Mexico, and fell in love with the popular vacation destination in the country's central highlands, which is known for its Spanish colonial architecture, charming cobbled streets and thriving art scene. 'Many people will tell you that they go to San Miguel and their checkbook comes out and they buy a property,' Gleason says. She decided to do the same in 2015 after finding a plot of land on a quiet street in the historic center of town.
Time Business News
19-07-2025
- Health
- Time Business News
Prostate Cancer: When to Treat and When to Monitor
You've probably heard the words 'prostate cancer', especially if you are more than 50 or a dear person goes through it. But a million dollars is a question of whether you immediately treat it or wait and see? Unlike many cancers, which require immediate action, prostate cancer sometimes plays by a different set of rules. This is right! Sometimes, nothing can be the best you can do right now. But how do you know when to work and when to catch? In cities such as Jaipur, where advanced medical treatment is easily accessible, selection is a real conversation starter between aggressive treatment and careful monitoring. Many patients begin the journey by detecting the best prostate cancer treatment in Jaipur, where their options become important. To understand prostate cancer, it is useful to paint the prostate: a small walnut-shaped gland under the bladder and next to the rectum. Most never give it a new idea until something goes wrong, but still, the organ calmly creates most of the fluids that carry semen during ejaculation. Prostate cancer begins when cells in the prostate start growing uncontrollably. Not all of these cells are aggressive, though. Some just sit there, minding their own business, growing at a snail's pace. Certain things increase your chances: Age (especially after 50), Family history, Being African-American, Obesity, Diet high in red meat and low in veggies. Sometimes prostate cancer whispers long before. Watch out for: Urin When cancer increases, then similar symptoms: blood in urine or semen, pain in the hips, back, or chest, erectile dysfunction PSA (PSA-Prostate-Specific Antigen) is a protein made by prostate cells. A high level doesn't always mean cancer, but it's a red flag that needs more checking. Not fun, but necessary. Your doctor inserts a gloved finger into the rectum to feel for lumps or hard spots on the prostate. When doctors see something unusual, they do a biopsy, which means taking a small needle core from the prostate to look for cancer cells. After an MR or CT scan can be ordered, the team helps check if the illness has spread beyond the gland. Low-risk cancer is slow-growing and unlikely to spread beyond the prostate, yet high-risk disease has features that suggest? It could move around the body more quickly. Pathologists combine two main patterns of cancer to make a Gleason score between 6 and 10. A score of 6 or 7 usually means that the tumor is mostly, while a score of 8 or more creates anxiety as the cells seem very aggressive. This means regular PSA testing, current biopsy, and monitoring. Ideal for low-risk cancer that does not increase or cause problems. Most are used for elderly patients or people with other health conditions. If the symptoms appear, treatment begins. Until then, this hand is closed. If the cancer is aggressive or causes symptoms: Radical prostatectomy – removes the prostate.e Radiation Treatment – Kill Cancer Cells Hormone Treatment – Cut the testosterone that drives cancer Chemotherapy – for advanced cases If urination hurts or the patient feels bone pain, waiting is rarely wise. A rising PSA level in many blood tests usually indicates a more aggressive disease and pushes many men against active treatment. A glygon score of 8 or higher or some rare, rapidly growing cell types is required soon to later. Gleeson can be carefully seen instead of relieving cancer that scores six or lower on the back, without pain. In men whose hearts, lungs, or other organs create a greater risk than cancer, careful observation may be more understandable than aggressive surgery. Some prostate tumors develop so slowly that they rarely change in ten years. In such cases, it seems to jump right into aggressive treatment, more like an exaggeration than progression. Simple options have power. Squeeze dishes with tomatoes, drink green tea instead of sugary drinks, cut down on red meat, and aim for a daily journey; Together, these habits can calm the body and mind. Steady watching beats hit-or-miss guesswork. Letting blood tests and scans slip means allowing tiny troubles the room to blossom into big surprises. The story of each cancer is one by one. A thoughtful urologist weighs the results of your test, general welfare, life goals, and feelings, which you like best. Living with uncertainty is draining. Byy explaining the why behind each option, a skilled urologist in Jaipur turns fog into practical road signs and soothes anxious nights. To determine whether the treatment or monitoring of prostate cancer is not a size-dependent landscape. It depends on your age, health, cancer phase, and how you feel about 'waiting and watching'. But the rest was secured – both options can be part of a successful strategy. The key is informed and open interaction with your doctor. Whether you need security or a game plan, consult a reliable urologist in Jaipur who can set you in the right direction. Not really. Certain types grow so slowly that they never cause trouble, yet they still need regular check-ins. Only if you skip the doctor visits, stay on schedule, and have a solid plan for low-risk patients. At the top of the list are tomatoes, broccoli, green tea, walnuts, and oily fish. High-grade, aggressive versions can move to bones and other organs if left untreated. It varies. Some men test every six months while others only once a year. click here for more articles TIME BUSINESS NEWS
Boston Globe
16-07-2025
- Boston Globe
Court system in N.H. launches internal review over bail granted to man before murder-suicide
Advertisement Multiple elected officials have called for Magistrate Stephanie Johnson, who authorized Gleason's release, to resign. Get N.H. Morning Report A weekday newsletter delivering the N.H. news you need to know right to your inbox. Enter Email Sign Up 'The bail system exists to balance the rights of the accused with the imperative of public safety,' Republican Representative Lori E. Korzen, who represents Berlin in the New Hampshire House, wrote in a letter to Johnson. 'In this instance, I believe that balance was not achieved, and the result was a preventable tragedy.' Two members of the five-person Executive Council signed Executive Councilor Joseph D. Kenney said in Advertisement 'That guy should have been left in jail until trial,' he said. Governor Kelly A. Ayotte noted last week that Johnson is the same magistrate judge who found herself at the center of a firestorm earlier this year following the release of Johnson was not the only court official involved in reviewing Gleason's bond conditions. Records show a bail commissioner and a Circuit Court judge also signed some of the relevant paperwork. Anthony J. Naro, a criminal defense and family law attorney, said it's appropriate to scrutinize outcomes in a case like this, but people should also speak up 'when a member of the judiciary is being unfairly vilified for doing a job that demands balance, restraint, and constitutional fidelity.' Johnson's decisions should be assessed based on the information that was available at the time and the legal principles that guide her work, Naro said. 'A fair and functional criminal justice system depends on every person who upholds the rights of the accused — even when doing so carries risk,' he added. To gather facts and gain clarity about what happened, MacDonald designated Supreme Court Associate Justice Melissa Countway and Circuit Court Administrative Judge Ellen V. Christo to review the relevant record and related matters involving Gleason, according to the Judicial Branch. Advertisement The court system's internal review is expected to work in concert with an examination undertaken by the state's Domestic Violence Fatality Review Committee. This story appeared in Globe NH | Morning Report, a free newsletter focused on New Hampshire, including great coverage from the Boston Globe and links to interesting articles elsewhere. To receive it via email Monday through Friday, Steven Porter can be reached at
